Sector Update: Health Care Stocks Higher in Late Afternoon Trading
Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index rising 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%.The iShares Biotechnology ETF (IBB) gained 0.8%
Sector Update: Health Care
Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index rising 1% and the Health Care Select Sector SPDR Fund (XLV) up 0.9%.The iShares Biotechnology ETF (IBB) gained 1%.
Verastem Spikes as Dosing for Lead Program Starts in China
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share.ASP Isotopes
Express News | Verastem Shares Are Trading Higher After the Company Announced the First Patient Has Been Dosed in a Phase 1/2 Trial in China, Conducted by GenFleet Therapeutics, Evaluating GFH375/VS-7375, a KRAS G12D Inhibitor
Express News | Verastem Inc: To Initiate Development Studies Outside of China After Evaluating Initial Dose Escalation Data From Phase 1 Study in China
Express News | Verastem Oncology Announces First Patient Dosed With Gfh375/Vs-7375, a Kras G12D (on/off) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration With Genfleet Therapeutics
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Announces Target Price $18
Truist Financial analyst Srikripa Devarakonda maintains $Verastem(VSTM.US)$ with a buy rating, and sets the target price at $18.According to TipRanks data, the analyst has a success rate of 49.5%
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
Verastem Is Maintained at Buy by Truist Securities
Verastem Is Maintained at Buy by Truist Securities
Truist Securities Maintains Buy on Verastem, Lowers Price Target to $18
Truist Securities analyst Srikripa Devarakonda maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $34 to $18.
Express News | Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Truist Securities Adjusts Price Target on Verastem to $18 From $34, Notes Recent Stock Pull Back; Maintains Buy Rating
Verastem (VSTM) has an average rating of buy and price targets ranging from $13 to $36, according to analysts polled by Capital IQ.
Express News | Verastem Inc : Truist Securities Cuts Target Price to $18 From $34
Express News | Verastem Inc Shares Hit Session Low After Volume Pickup, Last Down 6.8% at $2.74
Reported Wednesday, China's NMPA Approves GenFleet And Verastem Oncology's GFH375 For KRAS G12D Phase I/II Trials
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration (NMPA) has appro
Pancreatic Cancer on the Rise: How Biotech Firms Are Developing Groundbreaking Treatments
After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may ...
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions